Latest filing published 04 Jun 2025 for Iovance Biotherapeutics, INC..
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Jean-Marc Bellemin: trading record in brief
Jean-Marc Bellemin is a declared insider of Iovance Biotherapeutics, Inc. (finance chief), with filings sourced from SEC (Form 4). In total, 10 filings cover trades dated from 14 June 2022 to 2 June 2025.
Not one of the filings records a straightforward purchase or sale on the market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Most recently, on 4 June 2025, the filings show a share grant worth €6,860 in Iovance Biotherapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Jean-Marc Bellemin
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 8,789 shares0Common StockSEC:0001104659-25-056432:0
- 58,590 shares0Common StockSEC:0001104659-25-021062:0
- 23,438 shares0Common StockSEC:0001104659-24-097487:0
- 18,850 shares0Common StockSEC:0001104659-23-001600:0
- 18,850 shares0Common StockSEC:0001104659-22-071965:0
5 of 5 declarations
